Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.

@article{Schuster2014Anti318FFACBCPE,
  title={Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial.},
  author={David M. Schuster and Peter T. Nieh and Ashesh B. Jani and Rianot Amzat and F. DuBois Bowman and Raghuveer K. Halkar and Viraj A. Master and Jonathon A. Nye and Oluwaseun A. Odewole and Adeboye O. Osunkoya and Bital Savir-Baruch and Pooneh Alaei-Taleghani and Mark M. Goodman},
  journal={The Journal of urology},
  year={2014},
  volume={191 5},
  pages={1446-53}
}
PURPOSE We prospectively evaluated the amino acid analogue positron emission tomography radiotracer anti-3-[(18)F]FACBC compared to ProstaScint® ((111)In-capromab pendetide) single photon emission computerized tomography-computerized tomography to detect recurrent prostate carcinoma. MATERIALS AND METHODS A total of 93 patients met study inclusion criteria who underwent anti-3-[(18)F]FACBC positron emission tomography-computerized tomography plus (111)In-capromab pendetide single photon… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
24 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 24 extracted citations

Similar Papers

Loading similar papers…